Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy areas
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammat
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) in the US for the 2016-2017 influenza season.
Karolinska Institutet and AstraZeneca have today announced the appointment of Professor Christer Betsholtz as the new Director of their Integrated Cardio Metabolic Centre (ICMC) in Stockholm, Sweden.
Christer Betsholtz,PhD, is a leading scientific authority in the field of vascular biology with more than 300 publications. He is currently professor with tenure at Uppsala University and Karolinsk
Avtalet utökar den kommersiella räckvidden för anestetika och stödjer bolagets tydliga fokus på innovativa, nya läkemedel inom tre huvudterapiområden
AstraZeneca presented (at ASCO in the evening of June 5) results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial.
Osimertinib data reported at ASCO 2016 demonstrated improved neurological function in patients with EGFRm NSCLC and leptomeningeal disease Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout
AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of saxa/dapa (saxagliptin and dapagliflozin) tablets for the treatment of adults with type-2 diabetes. .
AstraZeneca today announced positive results from the Phase III FALCON trial comparing Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for hormone-receptor-positive (HR+) breast cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a wholly-owned subsidiary of AstraZeneca
Resultaten från den svenska SUPPORT-studien, som undersökt effekten på följsamhet och förebyggande insatser efter hjärtinfarkt med hjälp av en mobiltelefonapplikation, publiceras nu i American Heart Journal. Studien visar att de patienter som fick ett interaktivt patientverktyg i form av en ”mobil-app” i högre grad tog sitt blodproppshämmande läkemedel ticagrelor enligt läkarens ordination.
